Google teams up with GSK to develop ‘bioelectronic medicines’
Verily, formerly Google Life Sciences, teams up with GlaxoSmithKline to develop bioelectronic medicines that can “harness electrical signals in the body to treat chronic disease.” Both companies will invest up to $715 million to form Galvani Bioelectronics. It’ll be headquartered in the UK, with a second location in San Francisco.
One of their first projects will focus on the development of “miniaturized precision devices” that can help remedy disorders like type 2 diabetes. Both parties expect the deal to be approved before the end of the year, when Galvani plans to initially employ 30 scientists, engineers and clinicians.
